Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (2127)	1/30/2000 11:14:00 PM
From: Jumper	Respond to of 5582

>>every short trick in the book<< I have no position - just stopped by so widows and orphans would be saved.

To: DanZ who wrote (2127)	2/27/2001 12:14:10 AM
From: Mark Marcellus	Read Replies (1) \| Respond to of 5582

Earnings of $2.05 likely this year (my estimate). Dan, it looks like you missed by a bit. If I'm doing my math correctly, GUMM will post a loss of $.81 this year. And that's with the help of who knows how much in related party transactions from Zensano to prop things up. Also, about a year ago, some of us were guessing that GUMM may have achieved that Q4 1999 profit through stuffing the channel. This was heatedly denied by others. Yet, how else are we supposed to interpret this statement from the company? The Company's net sales for the quarter were $5.0 million, down from the prior year's level due to the sizeable introductory shipments to retailers of Zicam(TM) Cold Remedy in late 1999 when distribution channels were initially being filled. For the year-ended December 31, 2000, the Company reported net sales of $13.3 million, versus $15.5 million in 1999. You have always claimed to be a regular investor who aspires to being a stock analyst. If you wish to lay claim to that title, I don't see how you can continue to deny what is obvious to anyone with a clear mind and basic arithmetic skills.